Profound Medical Corp. announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market Tulsa-Pro for ablation of prostate tissue.
A drug developed by UCLA physician-scientists and chemists speeds up the regeneration of mouse and human blood stem cells after exposure to radiation. If the results can be replicated in humans, the compound could help people recover quicker from chemotherapy, radiation therapy and bone marrow transplants.
Patient portals can be a one-stop shop for patient access to health records and physicians. They can directly engage patients; provide access to their images; even help providers meet meaningful use requirements.
Mevion Medical Systems and C-RAD announced the integration between the C-RAD Catalyst PT and the Mevion S250i proton therapy system. The union of both products supports a seamless workflow with uninterrupted patient surface tracking and monitoring from setup through treatment.
Research on personalized medicines is gaining popularity in the cancer research industry, which has increased the need for effective and reliable diagnostic procedures and is expected to drive the growth of the whole slide imaging systems market. Growing demand for laboratory diagnosis procedures is also expected to fuel future growth, according to a new report from Persistence Market Research.
Henry Ford Cancer Institute is first-in-the-world to enroll a glioblastoma patient in the GBM AGILE Trial (Adaptive Global Innovative Learning Environment). The novel trial design and architecture is made possible by an international collaboration of experts in the care of patients with glioblastoma and the design of clinical trials. Led by the trial sponsor Global Coalition for Adaptive Research (GCAR), GBM AGILE is a seamless Phase II (Efficacy and Safety)/Phase III (Confirmatory) trial aimed at identifying the most effective therapies for patients with glioblastoma, the most aggressive form of brain cancer.
August 14, 2019 – Children’s veins are small and sometimes difficult to access during necessary medical treatment. When caregivers used ultrasound to guide placement of intravenous (IV) lines in children with presumed difficult access, they had higher success rates on their first attempt.
August 14, 2019 — NinePoint Medical Inc. announced it has received U.S. Food and Drug Administration (FDA) clearance to market the NvisionVLE Imaging System for use in the pancreas and bile duct. These anatomical indications add to the previously existing esophageal applications for NinePoint’s optical coherence tomography (OCT) imaging platform.
August 14, 2019 — Isoray announced a trio of studies recently reported at scientific meetings and published in medical journals that the company says illustrate the clinical utility of its Cesium Blu (formerly known as Cesium-131) treatment in radiation therapy applications. The company said the results will help grow market awareness of the range of clinical applications.
